Catalyst Pharmaceuticals Inc
CPRX
Jodie situation report
Catalyst Pharmaceuticals Inc's current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 18 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 4 directly disclosed connections are confirming.
- Revenue increased 5.6% versus the comparable filing period.
- CPRX's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CPRX's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind CPRX
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TEVATeva Pharmaceutical Industries LimitedcompetitorFeb 25, 2026 ▾
“63 Table of Contents With respect to ANDA filers, in January 2023, we received Paragraph IV Certification Notice Letters from three generic drug manufacturers (Teva Pharmaceuticals USA, Inc.”
BMRNBioMarin Pharmaceutical Inc.partnerNov 5, 2025 ▾
“On October 26, 2012 , the Company entered into a license agreement with BioMarin Pharmaceutical, Inc.”
Depended on by
EWTXEdgewise Therapeutics, Inc.partnerFeb 26, 2026 ▾
“In October 2023, the FDA granted AGAMREE (vamorolone), a novel steroid therapy, approval in Duchenne patients aged 2 years and older, and Catalyst Pharmaceuticals, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CPRX is currently a Follower in the organic co-movement group Digital Services & Software. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CPRX; it is not active in the latest market snapshot.